Details of the Drug

General Information of Drug (ID: DM1TWIE)

Drug Name
CFZ533
Indication
Disease Entry ICD 11 Status REF
Graves disease 5A02.0 Phase 2 [1]
Myasthenia gravis 8C6Y Phase 2 [1]
Rheumatoid arthritis FA20 Phase 2 [2]
Sjogren syndrome 4A43.20 Phase 2 [1]
Cross-matching ID
TTD ID
D0SD6V
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CD40L receptor (CD40) TTN6Y9A TNR5_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02291029) Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sj ren's Syndrome. U.S. National Institutes of Health.